Prestige Brands Holdings

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PBH reports record fiscal 2023 results, addresses inflation challenges

PBH's strong fiscal 2023 performance was highlighted, but challenges from inflation and foreign currency headwinds were acknowledged. The company is focused on leveraging opportunities for growth and remains committed to its long-term goals.

PBH reports resilient Q1 performance, anticipates high single-digit Q2 growth

PBH's Q1 performance demonstrated resilience with strong sales and margin improvements. While facing challenges in EBITDA and gross margin, the company's strategic focus on brand growth, debt reduction, and share buyback program positions it well for future opportunities. With a reaffirmed full-year outlook and anticipated Q2 growth, PBH remains focused on sustainable growth and financial discipline.

Prestige Brands reports solid Q3 earnings, eyes growth opportunities

Prestige Brands Holdings (PBH) delivered a solid performance in Q3 2023, driven by strong revenue growth, profitability, and strategic financial management.
While facing challenges such as gross margin decline and industry-wide inflationary pressures, the company remains focused on cost management and pricing strategies to sustain growth.
With opportunities for revenue growth, operational efficiency, and strategic planning in fiscal 2024, Prestige Brands is well-positioned for continued success and value creation.

Prestige Brands Holdings reports record fiscal '23 results and outlines growth strategies for fiscal '24

Prestige Brands Holdings delivered strong financial results in fiscal '23, with robust revenue growth and adjusted EPS. The company is focused on maintaining margins, reducing leverage, and capitalizing on growth opportunities in key segments. Management's strategic outlook for fiscal '24 includes revenue projections, EPS targets, and a commitment to disciplined capital allocation.

Prestige Brands Holdings (PBH) surpasses Q1 expectations amidst challenges

PBH's Q1 performance exceeded expectations with strong organic sales growth and improved gross margin despite cost pressures.
While facing challenges from cost increases and debt levels, PBH maintains a solid financial position with strong cash flow.
Opportunities lie in sustained revenue growth, market expansion, and operational efficiency enhancements for PBH in the coming quarters.

Prestige Brands reports robust Q2 results, eyes international growth

Prestige Brands Holdings delivered a solid performance in Q2, driven by strong sales, EPS growth, and debt reduction.
While facing challenges in North America and margin pressure, the company's international growth and e-commerce focus present opportunities for future expansion.
Maintaining a healthy financial position with strong cash flow and reaffirming full-year outlook underscores Prestige Brands' stability and growth potential.
Strategic management of expenses and leveraging brand success will be crucial for sustained growth and profitability in the competitive consumer goods market.

Prestige Brands Holdings reports solid Q3 performance and eyes growth

Prestige Brands Holdings delivered a strong Q3 performance with revenue exceeding expectations and a focus on maintaining market share and brand differentiation.
The company's financial discipline led to debt reduction and healthy free cash flow, while challenges include inventory coverage issues and evaluating M&A opportunities.
Opportunities for growth include exploring potential M&A deals, focusing on long-term financial targets, and capitalizing on international and North American segment growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the North American OTC Healthcare and International OTC Healthcare segments. The North American and International OTC Healthcare segments manage the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter ended June 30, 2021.

Prestige Consumer Healthcare Inc. Reports Fiscal 2022 First Quarter Results

Prestige Brands (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prestige Brands (PBH) Reports Next Week: What to Expect

Prestige Consumer (PBH) expanded its eye care portfolio by acquiring TheraTears and four other brands across the VMS and Cough & Cold categories.

Prestige Consumer (PBH) Adds TheraTears to Its Eye Care Portfolio

TARRYTOWN, N.Y., July 01, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige“ or the “Company”) today announced that it has completed the previously announced acquisition of TheraTears and other over-the-counter consumer brands.   The closing was finalized pursuant to the terms of the asset purchase agreement which was initially announced on May 27, 2021, under which Prestige agreed to acquire the brands from specialty pharmaceutical company, Akorn Operating Company LLC (“Akorn”), for $230 million in cash. The acquisition of TheraTears will further enhance Prestige's leading eye care portfolio and generate additional long-term growth opportunities for the Company.

Prestige Consumer Healthcare Completes Acquisition of TheraTears, Announces First Quarter Fiscal 2022 Earnings Results Date

Prestige Consumer's (PBH) solid e-commerce initiatives, together with its impressive marketing efforts and diverse brands, keep it well placed.

Prestige Consumer (PBH) Looks Poised on E-Commerce Strength

TARRYTOWN, N.Y., May 27, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE:PBH) today announced that it has entered into a definitive agreement to acquire a portfolio of over-the-counter consumer brands from specialty pharmaceutical company Akorn Operating Company LLC (“Akorn”) for $230 million in cash. The agreement is structured as an asset purchase that delivers anticipated tax benefits of ~$30 million and expected annual EBITDA of ~$20 million equating to a transaction valued at less than 10x pro-forma EBITDA. The transaction is estimated to add annual Revenues, Earnings Per Share and Operating Cash Flow of approximately $60 million, $0.10 and $13 million, respectively.

Prestige Announces Agreement to Expand Eye Care Offering with Acquisition of TheraTears

Prestige Consumer Healthcare Inc. (PBH) CEO Ron Lombardi on Q4 2021 Results - Earnings Call Transcript

Prestige Consumer's (PBH) fourth-quarter fiscal 2021 results reflect lower earnings and sales year over year due to pandemic-led disruptions in certain brands and tough comparisons with the year-ago period.

Prestige Consumer (PBH) Q4 Earnings Meet Estimates, Revenues Top

Prestige Brands (PBH) delivered earnings and revenue surprises of 0.00% and 3.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Prestige Brands (PBH) Q4 Earnings Match Estimates

TARRYTOWN, N.Y., May 06, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2021.

Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Fourth Quarter and Record Full-Year Results

Lower consumption patterns across certain categories and tough year-over-year comparisons might have hurt Prestige Consumer's (PBH) fourth-quarter fiscal 2021 performance.

Factors to Know Ahead of Prestige Consumer (PBH) Q4 Earnings

Earnings Preview: Prestige Brands (PBH) Q4 Earnings Expected to Decline

Prestige Consumer Healthcare (PBH) has been benefiting from a strong e-commerce performance as well as efficient saving efforts.

Here's Why Prestige Consumer Healthcare (PBH) Looks Promising

Malibu Boats

Spectrum Brands Hlds

Smith & Wesson Brands

Vista Outdoor

The rise in consumer confidence in March proves that people are showing faith in the economy, making this an ideal time to invest in consumer discretionary stocks PBH, VSTO, SPB, SWBI, MBUU.

Consumer Confidence Soars to One-Year High in March: 5 Picks

Central Garden & Pet Company

MCBC Hlds

The rise in consumer confidence in March proves that people are showing faith in the economy, making this an ideal time to invest in consumer discretionary stocks PBH, CENT, SPB, MCFT, MBUU.

Consumer Confidence Hits One-Year High: 5 Solid Stocks to Buy

Mueller Water

Phibro Animal Health

Procter & Gamble

Strayer Education

In anticipation of the Fed's big announcement on interest rates and inflation, Q.ai's Artificial Intelligence has brought you today's top buys.

Top Stocks To Buy Today As Bond Yields Pop And Nasdaq Plummets

Prestige Consumer (PBH) has been gaining on strength in the e-commerce business and cost-containment efforts. The company recently raised its guidance for fiscal 2021.

Here's Why Prestige Consumer (PBH) Stock Appears Promising

Dick's Sporting Goods

Hibbett Sports

The rise in consumer confidence in February proves that people are showing faith in the economy, which makes it an ideal time to invest in consumer discretionary stocks like Central Garden Pet Company(CENT) and DICKS Sporting Goods (DKS).

Consumer Confidence Hits Three-Month High: 4 Stocks to Buy

Prestige Consumer Healthcare (PBH) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Prestige Consumer Healthcare (PBH)

TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), has priced an upsized offering of $600 million in aggregate principal amount of 3.750% senior notes due 2031 (the “notes”) in a private offering. The sale of the notes is expected to be completed on or about March 1, 2021, subject to customary closing conditions. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.

Prestige Consumer Healthcare Inc. Announces Upsize and Pricing of $600 Million Senior Notes

TARRYTOWN, N.Y., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $500 million in aggregate principal amount of new senior notes due 2031 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.

Prestige Consumer Healthcare Inc. Announces Offering of $500 Million Senior Notes

Prestige Consumer Healthcare Inc. (PBH) CEO Ron Lombardi on Q3 2021 Results - Earnings Call Transcript

Prestige Brands (PBH) delivered earnings and revenue surprises of 5.19% and 2.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Prestige Brands (PBH) Q3 Earnings and Revenues Beat Estimates

Shares of Prestige Consumer (NYSE:PBH) moved higher by 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 0.00% over the past year to $0.81, which beat the estimate of $0.77.

Recap: Prestige Consumer Q3 Earnings

TARRYTOWN, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2020.

News for Prestige Brands Holdings Stock (PBH)